ArticleJAMA psychiatry2014
Longitudinal pattern of depressive symptoms around natural menopause.
Article in JAMA psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05282277 (Examining the Effects of Estradiol on Neural and Molecular Response to Rewards in Perimenopausal-Onset Anhedonia and Psychosis), which is not on this map. Cited by 90 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Examining the Effects of Estradiol on Neural and Molecular Response to Rewards in Perimenopausal-Onset Anhedonia and Psychosis
Who cites it
90 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of Psychosomatic and Genitourinary Syndrome Among Menopausal Women: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Characterizing the spectrum of distress symptoms in midlife women with perimenopausal depression.Journal of affective disorders · 2026Trial
- The short-term effects of estradiol, raloxifene, and a phytoestrogen in women with perimenopausal depression.Menopause (New York, N.Y.) · 2021Trial
- Pharmacologically Induced Sex Hormone Fluctuation Effects on Resting-State Functional Connectivity in a Risk Model for Depression: A Randomized Trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Trial
- Effects of Estradiol Withdrawal on Mood in Women With Past Perimenopausal Depression: A Randomized Clinical Trial.JAMA psychiatry · 2015Trial
- Distinct intrinsic neural connectivity of an emotion regulation network across the menopausal transition.Comprehensive psychoneuroendocrinology · 2026Article
- From perimenopause to neuroinflammation: Rethinking a case of late-onset mania.PCN reports : psychiatry and clinical neurosciences · 2026Article
- The Impact of Estradiol Dynamics During the Menopause Transition on Depression Risk: A Narrative Review of Estradiol's Neurobiological Mechanisms.Biological psychiatry · 2026Review
- Bionic Nanoparticle Hydrogel for Astrocyte-Targeted Estradiol Delivery Ameliorates Perimenopausal Depression via P2X7 Receptor Inhibition.Biomaterials research · 2026Article
- Efficacy and safety of estradiol/dydrogesterone combined with escitalopram in the treatment of anxiety and depression in perimenopausal women: a randomized controlled trial.Frontiers in physiology · 2026Article
- Longitudinal patterns and group heterogeneity of depressive symptoms during menopausal transition in middle-aged Korean women.Epidemiology and psychiatric sciences · 2025Article
- Creatine in women's health: bridging the gap from menstruation through pregnancy to menopause.Journal of the International Society of Sports Nutrition · 2025Review
- PTSD symptom clusters and alcohol use among midlife women Veterans.Journal of military, veteran and family health · 2025Article
- Urban-rural differences in influencing factors of depressive symptoms among Chinese perimenopausal women.Scientific reports · 2025Article
- Embracing change: Navigating menopause with the help of mobile health apps in Germany.Comprehensive psychoneuroendocrinology · 2025Review
- Depression Symptom Trajectories in Mothers With the FMR1 Premutation Vary by CGG Repeat Length: A Longitudinal Study of 73 Women Spanning 20-75 Years of Age.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2025Article
- Associations between menopause and body image.Przeglad menopauzalny = Menopause review · 2025Article
- The link between sex hormones and depression over a woman's lifespan (Review).Biomedical reports · 2025Review
- Follicle-stimulating hormone: More than a marker for menopause: FSH as a frontier for women's mental health.Psychiatry research · 2025Review
- Optimizing the diagnosis and treatment of depression in primary care: the emerging role of vortioxetine treatment.Frontiers in psychiatry · 2025Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
importanceAn increased risk of depressive symptoms has been associated with the transition to menopause, but the risk of depressive symptoms in the early postmenopausal years has not been well characterized.
objectivesTo identify within-woman changes in depressive symptoms during a 14-year period around menopause, determine associations of a history of depression with the pattern of depressive symptoms, and evaluate the rate of change in reproductive hormones as predictors of depressive symptoms following menopause. DESIGN, SETTING, AND
participantsA randomly identified, population-based sample in Philadelphia County, Pennsylvania, of 203 late-reproductive-age women who were premenopausal at baseline and reached natural menopause. MAIN OUTCOMES AND MEASURES: Center for Epidemiologic Studies Depression Scale.
resultsThe prevalence of high scores on the Center for Epidemiologic Studies Depression Scale decreased from 10 years before to 8 years after the final menstrual period (FMP), with a decrease of approximately 15% of baseline per year (odds ratio, 0.85; 95% CI, 0.81-0.89; P < .001). Relative to the FMP, the risk of depressive symptoms was higher in the years before and lower in the years after the FMP. Among women with a history of depression, the likelihood of depressive symptoms was more than 13 times greater overall and 8 times greater after menopause compared with women with no depression history. Among women who first experienced depressive symptoms approaching menopause, the risk of depressive symptoms declined after the FMP, with a significantly lower risk the second year after menopause. The risk of depressive symptoms after menopause decreased by 35% for each unit (SD) increase before the FMP in the log rate of change of follicle-stimulating hormone (odds ratio, 0.65; 95% CI, 0.46-0.91; P = .01). CONCLUSIONS AND RELEVANCE: The FMP was pivotal in the overall pattern of decreasing depressive symptoms in midlife women, with higher risk before and lower risk after the FMP. A history of depression strongly increased the risk both before and after menopause. Women who had no history of depression before the menopause transition had a low risk of depressive symptoms 2 or more years after the FMP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.